Critical Review: Dominari (NASDAQ:DOMH) & Cohen & Steers (NYSE:CNS)

Dominari (NASDAQ:DOMH) and Cohen & Steers (NYSE:CNS) are both finance companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Institutional and Insider Ownership

42.5% of Dominari shares are owned by institutional investors. Comparatively, 51.5% of Cohen & Steers shares are owned by institutional investors. 55.3% of Dominari shares are owned by insiders. Comparatively, 45.4% of Cohen & Steers shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Dominari and Cohen & Steers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	-51.61%	-235.37%	-163.66%
Cohen & Steers	28.82%	27.41%	19.58%

Volatility and Risk

Dominari has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Cohen & Steers has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Valuation and Earnings

This table compares Dominari and Cohen & Steers”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10 million	0.44	-$22.43 million	($5.39)	-0.42
Cohen & Steers	$556.12 million	6.74	$153.22 million	$3.26	22.38

Cohen & Steers has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Cohen & Steers, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Dominari and Cohen & Steers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1	0	0	0	1.00
Cohen & Steers	0	2	1	0	2.33

Cohen & Steers has a consensus price target of $88.00, suggesting a potential upside of 20.63%. Given Cohen & Steers’ stronger consensus rating and higher probable upside, analysts clearly believe Cohen & Steers is more favorable than Dominari.

Summary

Cohen & Steers beats Dominari on 13 of the 14 factors compared between the two stocks.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About Cohen & Steers

Cohen & Steers, Inc. is a holding company, which operates as an investment manager specializing in liquid real assets, which include real estate securities, listed infrastructure, commodities, natural resource equities, preferred securities, and other income solutions. It manages investment vehicles, such as institutional accounts, open-end funds and closed-end funds. The company was founded by Martin Cohen and Robert Hamilton Steers in 1986 and is headquartered in New York, NY.